NCT00150644View on ClinicalTrials.gov

A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a Hysterectomy

PHASE2CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions

Uterine FibroidsLeiomyoma

Interventions

DRUG

Asoprisnil

Asoprisnil 10mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

Asoprisnil 25 mg Tablet, oral Daily for 12 weeks

DRUG

Placebo

Placebo Tablet, oral Daily for 12 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Abbott

INDUSTRY